|Day Low/High||1.50 / 1.71|
|52 Wk Low/High||1.50 / 3.49|
- Conference Call Today at 8:30 a.m. EDT -
--Presentations to include late-breaker highlighting Endocyte's next generation CAR T-cell therapeutic platform—
Conference Call Today at 8:30 a.m. EST
The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 517,671 share decrease in total short interest for Endocyte Inc , to 1,553,889, a decrease of 24.99% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.
Anti-tumor activity demonstrated in dose escalation trials for EC1456 and EC1169
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Endocyte Inc , where a total volume of 785 contracts has been traded thus far today, a contract volume which is representative of approximately 78,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48.1% of ECYT's average daily trading volume over the past month, of 163,335 shares.